Scenarios that move IQV
IQVIA Holdings, Inc. Common Stock
Scenarios that move IQV: 25 analyses, 22 positive, 3 negative.
- · Ascendis Pharma receives positive CHMP opinion for TransCon CNP — ▲ · impact +7 · confidence low · horizon quarters
- · FDA expands ImmunityBio's Anktiva label for bladder cancer — ▲ · impact +10 · confidence low · horizon quarters
- · Syndax stock falls 16% as Phase II fibrosis study misses primary goal — ▼ · impact -8 · confidence low · horizon quarters
- · Mirum's Livmarli meets Phase III goal in ultra-rare liver diseases — ▲ · impact +8 · confidence low · horizon quarters
- · J&J beats Q3 earnings estimates, misses sales and raises outlook — ▲ · impact +25 · confidence low · horizon quarters
- · Roche reports positive Phase III eye drug data, FDA accepts BLA — ▲ · impact +26 · confidence medium · horizon quarters
- · Viking Therapeutics advances oral obesity drug to Phase III — ▲ · impact +22 · confidence medium · horizon quarters
- · argenx meets primary endpoint in Phase II celiac disease study — ▲ · impact +25 · confidence low · horizon weeks
- · Vaxcyte prices concurrent stock, warrant and convertible note offerings — ▲ · impact +10 · confidence low · horizon quarters
- · Spyre Therapeutics prices $350 million public stock offering — ▲ · impact +15 · confidence low · horizon quarters
- · Genmab and AbbVie report positive epcoritamab lymphoma trial results — ▲ · impact +14 · confidence low · horizon quarters
- · United Therapeutics stock rises 12.6% in trading — ▲ · impact +9 · confidence low · horizon quarters
- · Zealand Pharma reports positive survodutide Phase III weight loss results — ▲ · impact +22 · confidence low · horizon quarters
- · Lilly reports strong weight loss results for new drug — ▲ · impact +30 · confidence low · horizon quarters
- · DBV Technologies files FDA BLA for VIASKIN Peanut patch — ▲ · impact +25 · confidence low · horizon weeks
- · Mirum's Brelovitug meets goal in Phase III AZURE-1 study — ▲ · impact +8 · confidence low · horizon quarters
- · Kodiak Sciences shares soar 178% on positive wet AMD data — ▲ · impact +9 · confidence low · horizon quarters
- · Novo and Hengrui sign exclusive license for oral GLP-1/GIP drug — ▲ · impact +14 · confidence low · horizon quarters
- · Zymeworks updates 2026 guidance after Theravance acquisition — ▲ · impact +7 · confidence low · horizon quarters
- · Satellos wins FDA IND clearance for Forazapadin in FSHD — ▲ · impact +6 · confidence low · horizon quarters
- · Ionis reports positive late-stage results for two partnered drugs — ▲ · impact +17 · confidence low · horizon quarters
- · CHMP backs CORT's Lifyorli combo for ovarian cancer — ▲ · impact +10 · confidence low · horizon quarters
- · Sion cuts workforce nearly half after CF study failure — ▼ · impact -5 · confidence low · horizon quarters
- · Definium reports second Phase III success in anxiety program — ▲ · impact +18 · confidence low · horizon quarters
- · Amgen shares fall after Novartis' Pelacarsen misses Phase III goal — ▼ · impact -12 · confidence low · horizon quarters